Edition:
United Kingdom

People: argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

132.80EUR
4:39pm BST
Change (% chg)

€1.50 (+1.14%)
Prev Close
€131.30
Open
€131.90
Day's High
€133.70
Day's Low
€131.50
Volume
65,667
Avg. Vol
106,304
52-wk High
€133.70
52-wk Low
€54.30

De Bethizy, Joseph 

Dr. Joseph Donald De Bethizy has served as a Non-Executive Independent Member of the Board at argenx SE since May 2015. He has 30 years of experience in research and development and financial, business and operating management in the biotechnology and consumer products industry. He is the president of White City Consulting ApS. Previously, Dr. De Bethizy served as president and chief executive officer of Santaris Pharma A/S until October 2014, when the company was sold to Roche. From August 2000 to June 2012, Dr. De Bethizy was co-founder and chief executive officer of Targacept, Inc., a U.S. biotechnology company listed on Nasdaq. He currently serves on the supervisory boards of Albumedix A/S, Newron Pharmaceuticals SpA, Noxxon Pharma NV and AG, Rigontec GmbH and Proterris, Inc. From May 2013 to November 2014, he served as executive chairman of Contera Pharma ApS. He previously served on the boards of Asceneuron SA, Serendex Pharmaceuticals A/S, Enbiotix Inc., Targacept Inc. and Biosource Inc. Dr. De Bethizy has held adjunct appointments at Wake Forest University Babcock School of Management, Wake Forest University School of Medicine and Duke University. Mr. deBethizy holds a B. Sc. in biology from the University of Maryland, and an M. Sc. and a Ph. D. in toxicology from Utah State University. He is member of Research and Development committee, and the chairman of Remuneration and Nomination committee.

Basic Compensation

Total Annual Compensation, EUR 52,500
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 52,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --